利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.028 秒)

    DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY
    16.
    发明申请
    DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY 审中-公开
    用于激素替代治疗的DROSPIRENONE

    公开(公告)号：US20120220556A1

    公开(公告)日：2012-08-30

    申请号：US13356005

    申请日：2012-01-23

    申请人： Wolfgang HEIL ,  Juergen Hilmann ,  Ralph Lipp ,  Rolf Schuermann

    发明人： Wolfgang HEIL ,  Juergen Hilmann ,  Ralph Lipp ,  Rolf Schuermann

    IPC分类号： A61K31/585 ,  A61P25/00 ,  A61P15/00 ,  A61P9/00 ,  A61P19/10 ,  A61P17/00 ,  A61P5/30 ,  A61P25/22

    CPC分类号： A61K31/585 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/56 ,  A61K31/565 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6β,7β;15β;16β-dimethylene-3-oxo-17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.

    摘要翻译： 一种药物组合物，其包含作为第一活性成分的雌激素，例如雌二醇或戊酸雌二醇，其用量足以治疗与女性内源性雌激素水平不足相关的疾病和症状，并且作为第二活性成分6＆amp; ; 16和bgr-二亚甲基-3-氧代-17α-前 - 4-烯-21,17-碳内酯（屈螺酮，DRSP）足以保护子宫内膜免受雌激素的不利影响，其中包括治疗 绝经期，绝经期和绝经后妇女。 该组合物可用于激素替代疗法，并且可以作为多阶段药物制剂施用。 这种联合疗法可以包括DRSP和雌激素的连续，顺序或中断给药或其组合，每种任选以微粉化形式。

    DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY
    17.
    发明申请
    DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY 审中-公开
    用于激素替代治疗的DROSPIRENONE

    公开(公告)号：US20100093679A1

    公开(公告)日：2010-04-15

    申请号：US12640578

    申请日：2009-12-17

    申请人： Wolfgang HEIL ,  Juergen Hilmann ,  Ralph Lipp ,  Rolf Schuermann

    发明人： Wolfgang HEIL ,  Juergen Hilmann ,  Ralph Lipp ,  Rolf Schuermann

    IPC分类号： A61K31/56 ,  A61P15/00

    CPC分类号： A61K31/585 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/56 ,  A61K31/565 ,  A61K2300/00

    摘要： A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6β,7β;15β;16β-dimethylene-3-oxo-17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.

    摘要翻译： 一种药物组合物，其包含作为第一活性成分的雌激素，例如雌二醇或戊酸雌二醇，其用量足以治疗与女性内源性雌激素水平不足相关的疾病和症状，并且作为第二活性成分6＆amp; ; 16和bgr-二亚甲基-3-氧代-17α-前 - 4-烯-21,17-碳内酯（屈螺酮，DRSP）足以保护子宫内膜免受雌激素的不利影响，其中包括治疗 绝经期，绝经期和绝经后妇女。 该组合物可用于激素替代疗法，并且可以作为多阶段药物制剂施用。 这种联合疗法可以包括DRSP和雌激素的连续，顺序或中断给药或其组合，每种任选以微粉化形式。

    Pharmaceutical composition for use as a contraceptive
    18.
    发明申请
    Pharmaceutical composition for use as a contraceptive 审中-公开

    公开(公告)号：US20060058272A1

    公开(公告)日：2006-03-16

    申请号：US11266395

    申请日：2005-11-04

    申请人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker

    发明人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker

    IPC分类号： A61K31/56

    CPC分类号： A61K31/585 ,  A61K31/56 ,  A61K31/567 ,  A61K2300/00

    摘要： A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.

    Pharmaceutical composition for use as a contraceptive
    19.
    发明授权
    Pharmaceutical composition for use as a contraceptive 失效
    用作避孕药具的药物组合物

    公开(公告)号：US06787531B1

    公开(公告)日：2004-09-07

    申请号：US09654227

    申请日：2000-08-31

    申请人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker ,  Michael Huempel ,  Johannes W. Tack

    发明人： Juergen Hilman ,  Wolfgang Heil ,  Ralph Lipp ,  Renate Heithecker ,  Michael Huempel ,  Johannes W. Tack

    IPC分类号： A61K3156

    CPC分类号： A61K31/585 ,  A61K31/56 ,  A61K31/567 ,  A61K2300/00

    摘要： A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.

    摘要翻译： 作为第一活性剂的药物组合物包含对应于每日剂量的量的6β，7beta，15beta，16beta-二亚甲基-3-氧代-17α-孕-4-烯-21,17-碳内酯（屈螺酮） 在约2mg至约4mg的施用组合物上，并且作为第二活性剂，以对应于约0.01mg至约0.05mg的日剂量的量的17α-炔炔雌二醇（炔雌醇）与 一个或多个药学上可接受的载体或赋形剂。在一个具体实施方案中，组合物由多个单独包装的和单独可移除的每日剂量单位组成，放置在包装单元中并且用于口服给药至少连续21天，其中 所述日剂量单位包括屈螺酮和炔雌醇的组合。 该组合物可以进一步包含7个或更少的不含活性剂或仅含有炔雌醇的日剂量单位。